Celgene (CELG) – StreetInsider.com Reports
-
Celgene (CELG) granted FDA Orphan Drug Designations for treatment of alpha-thalassemia
-
Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG)
-
Bristol-Myers Squibb (BMY) Extends Recent Decline, Down Another 1.5%, Down 5% in Three Days
-
ServiceNow (NOW) to Replace Celgene (CELG) in the S&P 500; Thermo Fisher Scientific (TMO) Set to Join S&P 100
-
Exelon Corporation (EXC) to Replace Celgene (CELG) in NASDAQ-100 Index
-
ServiceNow (NOW) Gains on Chatter and as New CEO is Off and Running
-
ServiceNow (NOW) Ticks Higher on Chatter
-
Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week
-
Celgene (CELG) Receives CHMP Positive Opinion for REVLIMID in Combination With Rituximab for Treatment of Adult Patients With Previously Treated Follicular Lymphoma
-
Paulson's 13F Shows New Stake in Callon Petroleum (CPE), Overseas Shipholding (OSG), Increase in Horizon (HZNP) (more...)
-
Editas Medicine (EDIT), Celgene Corp. (CELG) Update Collaboration Agreement to Develop/Commercialize Autologous & Allogeneic T Cell Medicines
-
FDA Approves Celgene's (CELG) Reblozyl for Rare Blood Disorder
-
Standpoint Research Downgrades Celgene (CELG) to Hold
-
Celgene (CELG) PT Raised to $115 at SVB Leerink
-
Celgene (CELG) PT Raised to $110 at Wells Fargo
-
UPDATE: Baird Downgrades Celgene (CELG) to Neutral
-
Celgene (CELG) PT Raised to $109 at RBC Capital
-
Bristol-Myers posts better-than-expected results, Opdivo growth slows
-
Celgene (CELG) IV low into EPS and outlook
-
Bernstein Reinstates Celgene (CELG) at Market Perform
-
Celgene (CELG) Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed AML Met Primary and Key Secondary Endpoints
-
Amgen (AMGN) PT Raised to $218 at Piper Jaffray
-
Pre-Open Movers 08/26: (FBIO) (MDCO) (PBI) Higher (ALXN) (CREE) (AMGN) Lower (more...)
-
Surprise... Amgen (AMGN) Didn't Buy Alexion Pharma (ALXN)
-
Wall Street bounces as trade temperature cools
-
Bristol-Myers Squibb (BMY) Gains 5% on Celgene's Deal to Sell Otezla to Amgen
-
Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
-
Mizuho Securities Downgrades Celgene (CELG) to Neutral
-
Celgene (CELG) Announces U.S. FDA Approval of INREBIC as Treatment for Myelofibrosis
-
Paulson's 13F Shows New Stakes in Sotheby's (BID), Lyft (LYFT), Increase in Allergan (AGN), Sprint (S) (more...)
-
Baupost's 13F Shows New Stake in XPO Logistics (XPO), Increase in Bristol-Myers Squibb (BMY), CBS (CBS), Liquidated Celgene (CELG) (More...)
-
Third Point's 13F Shows New Stakes in Centene (CNC), GTT Communications (GTT), Tradeweb (TW), Increased Stake in Boston Scientific (BSX) (More...)
-
Celgene (CELG) PT Lowered to $96 at RBC Capital
-
Celgene (CELG) Tops Q2 EPS by 23c, Raises Gudiance
-
Bristol-Myers Squibb (BMY) Announces European Commission Approval of Pending Acquisition of Celgene (CELG)
-
Pfizer to spinoff, merge off-patent drugs unit with Mylan
-
Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
-
Pre-Open Movers 07/24: (JNCE) (SNPA) (EW) Higher; (IRBT) (TUP) (CAT) (more...)
-
After-Hours Movers 07/23: (JNCE) (SNAP) (EW) Higher; (IRBT) (SGEN) (GOOGL) (more...)
-
Jounce Therapeutics (JNCE) Reports Update on Strategic Collaboration with Celgene Corp. (CELG)
-
Celgene (CELG) Announces FDA Approval for OTEZLA for Treatment of Oral Ulcers Associated with Behcet's Disease
-
Zymeworks (ZYME) Announces Celgene (CELG) Selected Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration
-
Spark Therapeutics (ONCE) Trades Lower in Sympathy with Celgene (CELG)
-
Pre-Open Movers 06/24: (PCMI) (NERV) (PTN) (DFRG) (CZR) (ERI) (BMY) (CELG) (SPOT) (more)
-
Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal
-
Mirati Therapeutics (MRTX) PT Raised to $120 at Oppenheimer
-
Bristol-Myers Squibb Co. (BMY) Estimate Raised At Cowen
-
BeiGene (BGNE) Regains Full Global Rights to Tislelizumab from Celgene (CELG)
-
Celgene (CELG) Announces FDA and EMA Accept Applications for Ozanimod for Treatment of Relapsing Forms of MS
Back to CELG Stock Lookup